By PPN News Staff
The FDA revised the emergency use authorizations (EUAs) for two monoclonal antibody (mAb) treatments for COVID-19—bamlanivimab-etesevimab (Lilly) and casirivimab-imdevimab (Regen-COV, Regeneron)—to limit their use in areas where the omicron variant is widely circulating.
The treatments are highly unlikely to be active against the omicron variant, which is circulating throughout the country, the FDA said. Therefore, “these treatments are not authorized for use